Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | CAR T-cell therapy and BiTEs for myeloma

Philippe Moreau • 16 Jun 2020
EHA 2020
Multiple Myeloma Antibodies bb2121 CAR-T Idecabtagene vicleucel Teclistamab
CARTITUDE-1 KarMMa

Philippe Moreau, MD, Nantes University Hospital, Nantes, France, outlines results of the use of teclistamab, a BCMA x CD3 bispecific antibody in relapsed/refractory multiple myeloma (MM) patients, in addition to updates from KarMMa and CARTITUDE-1, evaluating the efficacy and safety of CAR T-cell therapies in MM. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Philippe Moreau

1:15
Overall survival data from the POLLUX trial: DRd versus Rd in patients with R/R multiple myeloma
Philippe Moreau • 15 Feb 2023
4:49
Factors to predict the outcomes of patients with R/R myeloma treated with CAR-T therapy
Philippe Moreau • 15 Feb 2023
3:02
Optimal treatment strategies for multiple myeloma
Philippe Moreau • 10 Sep 2021
1:59
Optimal treatment sequencing for relapsed/refractory myeloma
Philippe Moreau • 10 Sep 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals